Gliclazide is a sulfonylurea used to treat hyperglycemia in patients with type 2 diabetes mellitus. Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM).
- Mechanism
- Curator reviewed
Gliclazide binds to the β cell sulfonyl urea receptor (SUR1). This binding subsequently blocks the ATP sensitive potassium channels. The binding results in closure of the channels and leads to a resulting decrease in potassium efflux leads to depolarization of the β cells. This opens voltage-dependent calcium channels in the β cell resulting in calmodulin activation, which in turn leads to exocytosis of insulin containing secretorty granules.
- Primary indication
- For the treatment of NIDDM in conjunction with diet and exercise.Curator reviewed · 1 structured indication
- Formula / weight
- C15H21N3O3S · 323.41 g/mol (avg)
- First approval
- Canada, 2000
- Code names
- J3.151H · S-1702 · S-852 · SE-1702
- Brand names
Resolves to
BOVGTQGAOIONJV-BETUJISGSA-NSMILES[H][C@@]12CCC[C@]1([H])CN(C2)NC(=O)NS(=O)(=O)C1=CC=C(C)C=C1What you can answer from here — as of August 31, 2026
Which drugs share a target with Gliclazide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account